Novartis Ag (NVS) EBT Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
79.52% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
88.09% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
29.81% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-43.56% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-15.40% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
25.67% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-20.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.36% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
-3.80% |
| Dec 31, 2024 |
5.38% |
| Jun 30, 2024 |
-13.74% |
| Dec 31, 2023 |
1.90% |
| Jun 30, 2023 |
-21.84% |
| Mar 31, 2023 |
38.82% |
| Mar 31, 2022 |
6.04% |
| Dec 31, 2021 |
130.71% |
| Sep 30, 2021 |
3.03% |
| Jun 30, 2021 |
-10.03% |
| Mar 31, 2021 |
-6.41% |
| Dec 31, 2020 |
112.30% |
| Sep 30, 2020 |
0.96% |
| Jun 30, 2020 |
34.24% |
| Mar 31, 2020 |
-28.15% |
| Mar 31, 2019 |
39.20% |
| Dec 31, 2018 |
9.05% |
| Sep 30, 2018 |
56.21% |
| Mar 31, 2018 |
10,550.42% |
| Dec 31, 2017 |
9,652.83% |
| Sep 30, 2017 |
10,040.12% |
| Mar 31, 2017 |
9,084.72% |
| Sep 30, 2015 |
6,490.42% |
| Mar 31, 2015 |
-0.51% |
| Dec 31, 2014 |
-17.89% |
| Sep 30, 2014 |
1.46% |
| Mar 31, 2014 |
-1.81% |
| Sep 30, 2012 |
-40.00% |
| Jun 30, 2012 |
-37.31% |
| Mar 31, 2012 |
-38.77% |
